• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

性别和种族-族裔在代谢功能障碍相关脂肪性肝病中的差异:对 40166 人的分析。

Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 Individuals.

机构信息

Yong Loo Lin School of Medicine, National University of Singapore, Singapore 10 Medical Dr, Singapore, 117597, Singapore.

Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.

出版信息

Dig Dis Sci. 2024 Sep;69(9):3195-3205. doi: 10.1007/s10620-024-08540-4. Epub 2024 Jun 28.

DOI:10.1007/s10620-024-08540-4
PMID:38940975
Abstract

BACKGROUND

To overcome the limitations of the term "non-alcoholic fatty liver disease" (NAFLD), the term metabolic-associated steatotic liver disease (MASLD) was introduced. While epidemiologic studies have been conducted on MASLD, there is limited evidence on its associated sex and ethnic variations.

AIMS

This study assesses the differences across sex and race-ethnicity on the prevalence, associated risk factors and adverse outcomes in individuals with MASLD.

METHODS

Data retrieved from the National Health and Nutrition Examination Survey between 1999 to 2018 was analyzed. Prevalence, clinical characteristics, and outcomes were evaluated according to sex and race-ethnicity. Adverse outcomes and mortality events were analyzed using multivariate analyses.

RESULTS

Of 40,166 individuals included, 37.63% had MASLD. There was a significant increase in MASLD prevalence from 1999 to 2018 among Mexican Americans (Annual Percentage Change [APC] + 1.889%, p < 0.001), other Hispanics (APC + 1.661%, p = 0.013), NH Whites (APC + 1.084%, p = 0.018), NH Blacks (APC + 1.108%, p = 0.007), and females (APC + 0.879%, p = 0.030), but not males. Females with MASLD were at lower risk of all-cause (HR: 0.766, 95%CI 0.711 to 0.825, p < 0.001), cardiovascular disease-related (CVD) (SHR: 0.802, 95% CI 0.698 to 0.922, p = 0.002) and cancer-related mortality (SHR: 0.760, 95% CI 0.662 to 0.873, p < 0.001). Significantly, NH Blacks have the highest risk of all-cause and CVD-related mortality followed by NH Whites then Mexican Americans.

CONCLUSION

There has been an increase in prevalence in most race-ethnicities over time. While the change in definition shows no significant differences in previous associations found in NAFLD, the increased mortality in NH Whites relative to Mexican Americans remains to be explored.

摘要

背景

为了克服“非酒精性脂肪性肝病”(NAFLD)这一术语的局限性,引入了代谢相关脂肪性肝病(MASLD)这一术语。尽管已经对 MASLD 进行了流行病学研究,但关于其与性别和种族差异的证据有限。

目的

本研究评估了 MASLD 患者在患病率、相关危险因素和不良结局方面的性别和种族差异。

方法

分析了 1999 年至 2018 年期间从全国健康和营养检查调查中获取的数据。根据性别和种族评估患病率、临床特征和结局。使用多变量分析评估不良结局和死亡事件。

结果

在纳入的 40166 人中,有 37.63%患有 MASLD。自 1999 年至 2018 年,墨西哥裔美国人(APC+1.889%,p<0.001)、其他西班牙裔(APC+1.661%,p=0.013)、非西班牙裔白人(APC+1.084%,p=0.018)、非西班牙裔黑人(APC+1.108%,p=0.007)和女性(APC+0.879%,p=0.030)的 MASLD 患病率显著增加,但男性没有。患有 MASLD 的女性发生全因(HR:0.766,95%CI 0.711 至 0.825,p<0.001)、心血管疾病相关(SHR:0.802,95%CI 0.698 至 0.922,p=0.002)和癌症相关死亡(SHR:0.760,95%CI 0.662 至 0.873,p<0.001)的风险较低。值得注意的是,非西班牙裔黑人的全因和心血管疾病相关死亡率风险最高,其次是非西班牙裔白人,然后是墨西哥裔美国人。

结论

随着时间的推移,大多数种族的患病率都有所增加。虽然定义的变化并没有改变之前在 NAFLD 中发现的相关性,但与墨西哥裔美国人相比,非西班牙裔白种人的死亡率增加仍需进一步探讨。

相似文献

1
Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 Individuals.性别和种族-族裔在代谢功能障碍相关脂肪性肝病中的差异:对 40166 人的分析。
Dig Dis Sci. 2024 Sep;69(9):3195-3205. doi: 10.1007/s10620-024-08540-4. Epub 2024 Jun 28.
2
Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.甘油三酯-葡萄糖相关指标与非酒精性脂肪性肝病或代谢相关脂肪性肝病患者死亡的相关性。
Cardiovasc Diabetol. 2024 Jul 4;23(1):232. doi: 10.1186/s12933-024-02343-7.
3
Race/ethnic and sex disparities in the non-alcoholic fatty liver disease-abdominal aortic calcification association: The Multi-Ethnic Study of Atherosclerosis.非酒精性脂肪性肝病与腹主动脉钙化关联中的种族/族裔及性别差异:动脉粥样硬化多族裔研究
Atherosclerosis. 2017 Mar;258:89-96. doi: 10.1016/j.atherosclerosis.2016.11.021. Epub 2016 Nov 17.
4
The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢综合征严重程度对代谢功能障碍相关脂肪性肝病的种族和民族差异的影响。
PLoS One. 2024 Mar 15;19(3):e0299836. doi: 10.1371/journal.pone.0299836. eCollection 2024.
5
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.代谢相关脂肪性肝病和非酒精性脂肪性肝病的临床特征和病死率相似。
J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.
6
Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.美国非酒精性脂肪性肝病患者中不同种族和民族差异及不利健康社会决定因素的作用及其在各亚型中的表现。
Hepatol Commun. 2023 Dec 1;7(12). doi: 10.1097/HC9.0000000000000324.
7
Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.血清 25-羟维生素 D 与非酒精性脂肪性肝病:种族/民族差异重要吗?来自 MESA 队列的研究结果。
Nutr Metab Cardiovasc Dis. 2020 Jan 3;30(1):114-122. doi: 10.1016/j.numecd.2019.09.004. Epub 2019 Sep 10.
8
Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.美国非酒精性脂肪性肝病患病率、严重程度和结局的种族和民族差异:系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2018 Feb;16(2):198-210.e2. doi: 10.1016/j.cgh.2017.09.041. Epub 2017 Sep 29.
9
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.MAFLD 标准比 MASLD 标准更能预测慢性肾脏病的风险。
Ann Hepatol. 2024 Sep-Oct;29(5):101512. doi: 10.1016/j.aohep.2024.101512. Epub 2024 May 6.
10
Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.甘油三酯葡萄糖相关参数对美国代谢功能障碍相关脂肪性肝病患者全因和心血管死亡率的预后影响。
Cardiovasc Diabetol. 2024 Jun 1;23(1):188. doi: 10.1186/s12933-024-02287-y.

引用本文的文献

1
MAFLD outperforms NAFLD in identifying metabolic dysfunction in U.S. adolescents: a NHANES 2017-2020 analysis.在美国青少年中,MAFLD在识别代谢功能障碍方面优于NAFLD:一项2017 - 2020年美国国家健康与营养检查调查(NHANES)分析。
BMC Gastroenterol. 2025 Aug 25;25(1):617. doi: 10.1186/s12876-025-04170-w.
2
Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones.脂肪肝指数、代谢功能障碍相关脂肪性肝病与肾结石风险之间的关联。
Kidney Blood Press Res. 2025;50(1):115-130. doi: 10.1159/000543404. Epub 2025 Jan 2.
3
Small intestinal bacterial overgrowth and metabolic dysfunction-associated steatotic liver disease.

本文引用的文献

1
Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.美国非酒精性脂肪性肝病患者中不同种族和民族差异及不利健康社会决定因素的作用及其在各亚型中的表现。
Hepatol Commun. 2023 Dec 1;7(12). doi: 10.1097/HC9.0000000000000324.
2
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.回复:关于新的脂肪性肝病命名的多学会德尔菲共识声明。
Hepatology. 2024 Mar 1;79(3):E93-E94. doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.
3
Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study.
小肠细菌过度生长与代谢功能障碍相关脂肪性肝病
Front Nutr. 2024 Dec 17;11:1502151. doi: 10.3389/fnut.2024.1502151. eCollection 2024.
4
Addressing the alarming link between nonalcoholic fatty liver disease and cardiovascular mortality in men.解决男性非酒精性脂肪性肝病与心血管死亡率之间令人担忧的联系。
World J Cardiol. 2024 Sep 26;16(9):502-507. doi: 10.4330/wjc.v16.i9.502.
按种族和民族划分的非酒精性脂肪肝的肝脏和死亡率结局的差异:一项纵向真实世界研究。
Clin Mol Hepatol. 2023 Oct;29(4):1002-1012. doi: 10.3350/cmh.2023.0205. Epub 2023 Sep 11.
4
99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.99%的非酒精性脂肪性肝病患者符合代谢功能障碍相关脂肪性肝病标准,因此其自然病史相同。
J Hepatol. 2024 Feb;80(2):e76-e77. doi: 10.1016/j.jhep.2023.08.026. Epub 2023 Sep 9.
5
Socioeconomic disparities in the management and outcomes of acute myocardial infarction.社会经济差异对急性心肌梗死的管理和结果的影响。
Heart. 2023 Dec 20;110(2):122-131. doi: 10.1136/heartjnl-2023-322601.
6
Can we use old NAFLD data under the new MASLD definition?在新的代谢相关脂肪性肝病(MASLD)定义下,我们能否使用旧的非酒精性脂肪性肝病(NAFLD)数据?
J Hepatol. 2024 Feb;80(2):e54-e56. doi: 10.1016/j.jhep.2023.07.021. Epub 2023 Aug 2.
7
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
8
Global incidence and prevalence of nonalcoholic fatty liver disease.全球非酒精性脂肪性肝病的发病率和患病率。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14.
9
Open Access Budget Impact Assessment Tools: A Welcome Step in Supporting Evidence-Informed Policy Decisions.开放获取预算影响评估工具:迈向支持基于证据的政策决策的可喜一步。
Can J Cardiol. 2022 Oct;38(10):1485-1487. doi: 10.1016/j.cjca.2022.07.003. Epub 2022 Sep 12.
10
Health disparities in chronic liver disease.慢性肝脏疾病中的健康差异。
Hepatology. 2023 Apr 1;77(4):1382-1403. doi: 10.1002/hep.32743. Epub 2022 Sep 4.